Business
HeartBeam to Host Virtual Roadshow Webinar on Tuesday September 20, 2022 at 4:30 p.m. Eastern Time
Unveils New Video Featuring the HeartBeam AIMI™ and AIMIGo™ Technology SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a developmental
About this update from Heartbeam, Inc.
[{"type":"text","content":"\nUnveils New Video Featuring the HeartBeam AIMI™ and AIMIGo™ Technology\n\n SANTA CLARA, Calif.--(BUSINESS WIRE)--\nHeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced that it will host a virtual roadshow webinar on Tuesday September 20, 2022, at 4:30 p.m. Eastern Time.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005339/en/(Graphic: Business Wire)\nDuring the webinar, a new video showcasing the HeartBeam AIMIGo platform technology for use in heart attack detection will be unveiled. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies.\n\nThe video is available in the company’s investor relations section here.\n\nThe video takes viewers behind the scenes for a featured look at the HeartBeam AIMIGo technology, a medical grade solution with a 510(K) regulatory pathway that the company expects to submit to FDA for clearance by the end of the year. Once cleared, for the first time outside of a medical setting, the Company believes that AIMIGo can enable patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be initiated, if needed. The goal of HeartBeam’s technology is to offer more accurate heart attack detection to triage patients and expedite treatment and save healthcare dollars.\n\nHeartBeam’s CEO and founder Branislav Vajdic, PhD, CFO Rick Brounstein, and Chief Business Officer Jon Hunt, PhD, will host the virtual roadshow webinar, during which they will review recent announcements, including its 510(k) application to the FDA for its HeartBeam AIMI™ platform technology, ongoing initiatives and discuss key 2022 and 2023 milestones. The webinar will be accompanied by a presentation and followed by a question-and-answer session from webcast viewers, which can be accessed via the webcast link.\n\nTo access the webinar, please use the following information:\n\n\n\nDate:\n\n\n\n\n\nTuesday September 20, 2022\n\n\n\n\n\nTime:\n\n\n\n\n\n4:30 p.m. Eastern time (1:30 p.m. Pacific time)\n\n\n\n\n\nDial-in:\n\n\n\n\n\n1-877-704-4453\n\n\n\n\n\nInternational Dial-in:\n\n\n\n\n\n1-201-389-0920\n\n\n\n\n\n...